Robert L. van Nostrand, Director at Intra-Cellular Therapies, Inc. (ITCI), sold 40,000 shares at $72.71 ($2.9M) on 2024-02-27, disclosed to the SEC on 2024-02-28.
Open-market sale of $2.9M ITCI by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $72.71 | 9,651 | $702K | 24.1% |
| 2 | $72.71 | 9,651 | $702K | 24.1% |
| 3 | $73.14 | 10,349 | $757K | 25.9% |
| 4 | $73.14 | 10,349 | $757K | 25.9% |
| Total | $72.93 avg | 40,000 | $2.9M | 100% |
| Filing → |
| ITCI | SELL | 2023-04-19 | $630K | — | Filing → |
| ITCI | SELL | 2022-08-12 | $1.7M | — | Filing → |
| MBLX | BUY | 2012-12-04 | $21K | — | Filing → |